Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy, safety and tolerability of 4 regimen with 3 doses of ZK 219477 [sagopilone] (16 and 12 mg/m2 body surface area as 3-hour infusion or 22 mg/m2 body surface area as 30-minute or 3-hour infusion) in patients with metastatic breast cancer

X
Trial Profile

Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy, safety and tolerability of 4 regimen with 3 doses of ZK 219477 [sagopilone] (16 and 12 mg/m2 body surface area as 3-hour infusion or 22 mg/m2 body surface area as 30-minute or 3-hour infusion) in patients with metastatic breast cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sagopilone (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Bayer; Bayer HealthCare Pharmaceuticals
  • Most Recent Events

    • 13 Dec 2009 Results presented at the 32nd Annual San Antonio Breast Cancer Symposium.
    • 13 Dec 2009 Primary endpoints not met according to an abstract presented at the 32nd Annual San Antonio Breast Cancer Symposium.
    • 13 Jan 2009 Additional trial identifier (91464) added as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top